Fulcrum Therapeutics News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

13.05.24	Fulcrum Therapeutics Stock Climbs In Pre-market On License Deal With Sanofi For Losmapimod (RTTNews)
22.08.23	Fulcrum Says FDA Lifts Clinical Hold On FTX-6058 For Sickle Cell Disease; Stock Climbs In Premarket (RTTNews)
25.06.23	FULC DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action - FULC (PR Newswire)
17.06.23	ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action - FULC (PR Newswire)
13.06.23	ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FULC (PR Newswire)
03.06.23	FULC INVESTOR NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FULC (PR Newswire)
27.05.23	ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FULC (PR Newswire)
21.05.23	ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FULC (PR Newswire)
12.05.23	ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FULC (PR Newswire)
04.01.23	Fulcrum Therapeutics Names Robert Gould As Interim CEO After CEO Bryan Stuart Departs (RTTNews)
16.08.22	Fulcrum Therapeutics Prices Public Offering Of 9.59 Mln Shares At $7.82/shr (RTTNews)
30.06.21	Will Fulcrum's FTX-6058 Show Promise As Sickle Cell Disease Therapy In Phase I Trial? (RTTNews)
24.06.21	Fulcrum : Phase 2b Trial On Facioscapulohumeral Muscular Dystrophy Fails To Meet Main Goal (RTTNews)
12.05.21	Fulcrum : FDA Grants Fast Track Designation To Losmapimod For Potential FSHD Treatment (RTTNews)
29.01.20	Fulcrum Therapeutics: FDA Grants Orphan Drug Designation To Losmapimod (RTTNews)
09.01.20	Fulcrum Therapeutics (FULC) Up 65% In A Month, IPO Lockup Expires On Jan.14 (RTTNews)
23.12.19	Healthcare IPOs That Disappointed Investors In 2019 (RTTNews)
12.11.19	Today's Top 5 Gainers In Healthcare Sector (CABA, INMD, AQST…) (RTTNews)
10.10.19	Healthcare Stocks That Plunged To New Lows(AEZS,SRNE,TROV...) (RTTNews)
20.08.19	5 Top Gainers In Healthcare Sector (TROV, FULC, ARDX…) (RTTNews)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V